|Slideshows|February 21, 2019

7 Evidence-Based Insights About ADHD

This collection summarizes ADHD as it relates to bipolar disorder and borderline personality disorders; culturally competent care for the African-American population; issues with sleep disorders; and more.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

New CTx-1301 Data Affirms Pharmacokinetic Profile to Treat ADHD

ByJessica Walters

August 11th 2026

New Consensus Guidelines Classify Stuttering as a Brain-Based Disorder

ByGerald A. Maguire, MD

August 11th 2026

Centanafadine in ADHD: Clinical Significance of the First Triple Reuptake Inhibitor for ADHD

ByRaman Baweja, MD

August 3rd 2026

A New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval

ByJessica Walters,Raman Baweja, MD

July 31st 2026

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

ByJessica Walters

July 30th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

7 Evidence-Based Insights About ADHD

Related Content

New CTx-1301 Data Affirms Pharmacokinetic Profile to Treat ADHD

New Consensus Guidelines Classify Stuttering as a Brain-Based Disorder

Centanafadine in ADHD: Clinical Significance of the First Triple Reuptake Inhibitor for ADHD

A New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jersey City Psychiatry

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Interdisciplinary Consensus Guidelines on Stuttering (Childhood-Onset Fluency Disorder): Addressing Issues in Diagnosis, Treatment, and Unmet Needs

New in Narcolepsy: Pharmacology Updates

New CTx-1301 Data Affirms Pharmacokinetic Profile to Treat ADHD

Morning Rounds: News From August 3-9

New Consensus Guidelines Classify Stuttering as a Brain-Based Disorder